Fig. 4.
GVHD response to visilizumab.
Shown are the percentages of evaluable patients with a complete (solid bars) or partial (stippled bars) response to single (left) or multiple (right) doses of visilizumab at weekly time points. The overall response is shown in panel A, and organ responses are shown for skin (B), liver (C), or gut (D). The number of patients evaluated for response is indicated above each bar for each time point.